Aarey Drugs & Pharmaceuticals has scheduled its 36th Annual General Meeting for Wednesday, September 30, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means.

The company notified the Bombay Stock Exchange and the National Stock Exchange regarding the book closure period, which runs from September 24, 2026, to September 30, 2026. This action is taken pursuant to Regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Book Closure Details

The Registers of Members and Share Transfer books will remain closed on both days inclusive. Shareholders holding shares as of the record date will be eligible to attend the meeting and vote on resolutions.

Nimit Ghatalia, Director of the company, issued the notification on September 8, 2026. The company manufactures bulk drugs and imports solvents and chemicals.

AGM Agenda and Resolutions

The primary business includes receiving, considering, and adopting the audited financial statements for the year ended March 31, 2026. Additionally, shareholders will vote on the reappointment of Mrs. Bina Ghatalia as a director, who retires by rotation and is eligible for reappointment.

Special business involves the approval of related party transactions. The board seeks consent for contracts with related parties, including loans and advances, up to specified limits during the financial year. These transactions are deemed to be in the ordinary course of business and on arm's length basis.

E-Voting Process

Shareholders can cast their votes electronically between September 27, 2026, at 9:00 am and September 29, 2026, at 5:00 pm. The cut-off date for e-voting eligibility is September 23, 2026. Institutional shareholders are required to submit board resolutions authorizing their representatives to vote.

Aarey Drugs & Pharmaceuticals Limited reported a sharp expansion in top-line growth for the quarter ended June 30, 2026, with revenue rising 145% year-on-year. However, this volume surge was not matched by profitability, as net profit before tax contracted significantly.

**Aarey Drugs & Pharmaceuticals Limited** posted total income from operations of ₹4,643.05 lakh for Q1FY26, compared to ₹1,894.29 lakh in the corresponding quarter of FY25. Despite the robust revenue performance, the company’s net profit before tax, exceptional and extraordinary items fell 59.7% to ₹51.56 lakh, down from ₹128.01 lakh in Q1FY25.

Financial Performance Overview

The company’s full-year audited results for FY26 showed total income of ₹10,736.08 lakh and a net profit before tax of ₹137.72 lakh. For the current quarter, earnings per share (basic and diluted) stood at ₹0.36 each, marginally higher than the ₹0.35 recorded in Q1FY25.

What the Numbers Show

The divergence between revenue growth and profit contraction indicates significant margin compression during the quarter. While sales more than doubled, the absolute profit contribution dropped by nearly 60%. This suggests that cost structures or input prices may have risen disproportionately to the revenue gains, eroding operational efficiency despite the strong topline momentum.

Corporate Governance

The Board of Directors approved the unaudited standalone financial results at its meeting held on August 14, 2026. The results were reviewed by the Audit Committee in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial statements are available on the company’s website and stock exchange portals.